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1684-1182/Copyright ª 2014, TaiwanThe immunity of human immune cells and their ability to inhibit Mycobacterium tuberculosis
(MTB) are key factors in the anti-MTB effect. However, MTB modulates the levels and activity
of key intracellular second messengers, such as calcium, to evade protective immune re-
sponses. Recent studies suggest that inhibiting L-type calcium channel in immune cells using
either antibodies or small interfering RNA increases calcium influx, upregulates the expression
of proinflammation genes, and reduces MTB burden. First, we will review the key factors in
calcium-signaling pathway that may affect the immunity of immune cells to MTB infection.
Second, we will focus on the role of calcium channels in regulating cellular immunity to
MTB. Finally, we will discuss the possibility of using calcium-channel blockers as anti-MTB
chemotherapy drugs to enhance chemotherapy effects, shorten treatment period, and over-
come drug resistance.
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Tuberculosis (TB) is a chronic infectious disease caused by
Mycobacterium tuberculosis (MTB). Although MTB may
invade various organs, it mainly affects the lungs, causing
pulmonary TB. In 2012, more than 20 million people
worldwide were infected with MTB, including 8.6 millionby Elsevier Taiwan LLC. All rights reserved.
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the prevention and treatment of TB are the large amount of
floating population and hidden infections, the slow progress
in treating multidrug-resistant TB (MDR-TB), and the co-
infected immune-compromised population.2 At present,
chemotherapy alone is not enough to cope with these
challenges. Therefore, there is a necessity to develop new
treatment methods, including the use of an integrated
approach to develop new drugs, immunotherapy, and gene
therapy.
It was found recently that during MTB infection, increase
in calcium influx or release of calcium from intracellular
calcium pool activates the intracellular calcium-signaling
pathway, thereby activating the gene expression of anti-
infection and immune-protective proteins in immune cells,
especially macrophages.3,4 This increase in calcium
signaling enhances the phagocytic activity and the anti-MTB
ability of immune cells, ultimately enhancing the anti-MTB
ability of the whole immune system. As the key player in
maintaining the intracellular calcium level, calcium chan-
nels have crucial roles in regulating the calcium-signaling
pathway. Blocking of L-type calcium channel with verap-
amil, which is an L-type calcium channel-specific blocker,
enhances the intracellular calcium level and triggers the
downstream calcium-signaling pathway, ultimately acti-
vating the anti-infection gene expression.3 We herein re-
view the findings on immune cell calcium signaling during
MTB infection, discuss the mechanism behind the anti-MTB
effect of verapamil, assess the possibility of using verap-
amil as a candidate in combined chemotherapy, and pro-
pose future research directions.Intracellular calcium-signaling pathway and its
physiological significance
As a key intracellular second messenger, calcium has crucial
physiological roles in muscle contraction, synaptic trans-
mission and plasticity, cell motility, fertilization, cell
growth, cell proliferation, and gene expression. It is also
involved in regulating the enzyme activity, the ion-channel
permeability, and cytoskeleton components.5 The resting
intracellular calcium concentration is usually maintained at
10e100 nmol/L. To maintain such low intracellular calcium
levels, calcium is actively transported out of the cell or into
the endoplasmic reticulum (ER), sarcoplasmic reticulum,
and mitochondria. When calcium signaling is activated,
calcium enters into the cell through cell-surface calcium
channels and activates the ER calcium channels, which
release more calcium from the intracellular calcium store.
The specific signal may trigger the sudden increase of
intracellular calcium levels to 500e1000 nmol/L.6 The most
common calcium-signaling pathway is the phospholipase C
(PLC) pathway. Many cell-surface receptors, including G
protein-coupled receptors and receptor tyrosine kinases,
can activate the PLC pathway. The PLC hydrolyzes mem-
brane phospholipids (phosphatidylinositol 4,5-bisphosphate)
to generate inositol trisphosphate (IP3) and diacylglycerol
(DAG), which are two classic second messengers.6 DAG ac-
tivates protein kinase C (PKC), whereas IP3 spreads to the ER
and binds to the IP3 receptor (IP3R). The IP3R is an ER calcium
channel that is responsible for calcium release from the ER.Gene expression can then be activated by calcium mainly
through the following: the ternary complex factor pathway,
the serum response factor pathway, and the cyclic adeno-
sine monophosphate (AMP) response element pathway.
Gene expression is activated through different calcium-
signaling pathways in different cell types.7
The possible calcium-signaling pathway in
immune cells
The exact calcium-signaling pathway in immune cells is not
clear. However, it may regulate cell function in the
following manner (Fig. 1): the extracellular calcium enters
into the cells through the cell-membrane calcium channel,
including selective calcium channels, such as voltage-gated
calcium channels (VGCCs), or nonselective calcium chan-
nels, such as purine receptor (P2X7), cyclic nucleotide-
gated ion channels (CNGs), and canonical transient recep-
tor potential channels (TRPCs). VGCC is activated by
changes in membrane potential, P2X7 by adenosine
triphosphate (ATP), CNG by cAMP, and TRPC by PLC or DAG.
On the one hand, calcium entering into the cell can directly
activate calmodulin (CaM) and PKC to produce a series of
cascading effects.8 Calcium activates downstream kinases
through the mitogen-activated protein kinase (MAPK)
pathway, and MAPK regulates the phosphorylation of
several transcription factors, including C-myc gene, the
MAPK-interacting kinase (Mnk), and cAMP response element
binding protein (CREB).9 MAPK regulates gene transcription
by modulating the level and activity of transcription fac-
tors, which is very important for cell growth, differentia-
tion, and apoptosis. On the other hand, calcium enters into
cells and activates the calcium channels on the ER surface,
such as the ryanodine receptor (RyR), to induce more cal-
cium release from the ER (calcium-induced calcium release
or CICR).10 Meanwhile, Ras and Src participate in the syn-
thesis of IP3 in the presence of PLC, and activate the IP3R on
ER surface to release calcium. IP3 activates the calcium-
signaling pathway mainly through PLC and phosphoinosi-
tide 3-kinase, which activate a series of infection and cell
differentiation-related transcription factors, such as nu-
clear factor of activated T cells and CREB.6
The role of ion channels in anti-TB therapy
The role of purine receptors in TB pathology and
cellular immunity
Understanding the mechanism of TB pathology and cellular
immunity from the ion-channel perspective is a new field of
study. The current studies focus on the role of purine re-
ceptor P2X7 in TB infection and immunity, as well as on the
anti-TB therapy targeting P2X7. Human P2X7 is a membrane
ligand-gated ion channel widely distributed in immune
cells.11 It has two transmembrane domains and is activated
by extracellular ATP.12,13 In macrophages and myeloid cells,
activation of P2X7 receptor byATP induces Kþefflux andCa2þ
influx, and triggers the processing and secretion of cytokines
interleukin-1b (IL-1b), IL-18, and IL-12.11 IL-12 synergizes
with IL-18 or IL-1b for the production of interferon-g from
Figure 1. Possible calcium-signaling pathways in immune cells. Extracellular calcium enters the cell through membrane calcium
channels, including selective calcium channels, such as VGCC, or nonselective calcium channel, such as P2X7, CNG, and TRPC.
Calcium activates CaM and PKC, and then further triggers downstream protein kinases (such as MAPKs) and initiates gene
expression. Calcium also activates ER surface calcium channels, such as RyR, to achieve CICR. Meanwhile, IP3 is also produced in
the presence of Ras, Src, and PLC and activates the ER IP3R to release calcium. Calcium signaling regulates the expression of a
range of gene expression related to anti-infection and cell differentiation, such as NFAT and CREB. CaM Z calmodulin;
cAMP Z cyclic adenosine monophosphate; CBP Z CREB binding protein; CICR Z calcium-induced calcium release; CNG Z cyclic
nucleotide-gated ion channel; CREBZ cyclic adenosine monophosphate response element binding protein; DAGZ diacylglycerol;
ER Z endoplasmic reticulum; GPCR Z G protein-coupled receptor; HDAC Z histone deacetylase; IKK Z I kappa B kinase;
IP3Z inositol triphosphate; IP3RZ IP3 receptor; MAPKZ mitogen-activated protein kinase; MEF2Z myocyte enhancer factors 2;
NFAT Z nuclear factor of activated T cells; PI3K Z phosphatidylinositol-4,5-bisphosphate 3-kinase; PIP2 Z phosphatidylinositol-
4,5-bisphosphate; PKCZ protein kinase C; PLCZ phospholipase C; RTKZ receptor tyrosine kinase; SERCA Z sarco/endoplasmic
reticulum Ca2þ-adenosine triphosphatase; TRCPZ transient receptor potential channels; VGCCZ voltage-gated calcium channel.
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within minutes following the activation of P2X7, including
the dissociation of certain surface molecules, the release of
microparticles/exosome, membrane shrinkage, and
apoptosis. Activation of P2X7 requires high concentrations of
ATP (>100 mmol/L). However, it is not clear where such high
concentrations of ATP are present, and they may possibly
exist in a confined space such as bone.11
MTB can survive in immune cells and infect humans due its
ability to escape from immune defense by several ways,
including reactive oxygen intermediate, reactive nitrogen
intermediates, and lysosomal enzyme destruction by mono-
cytes/macrophages (M/M). The latter is now considered a
key step in MTB survival, including the ability to prevent the
fusion of lysosome andMTB-infected phagosome, that is, the
formation of active phagocytic lysosomes.15 The death of
MTB-infected M/M is often considered the cause of MTBspread, and M/M activation is widely regarded as an impor-
tant step of MTB killing. However, the activated M/M can
survive for a long time and offer the potential habitat for
MTB, or even support the growth of MTB. Because necrosis
leads to the release of intracellular substances, whereas
apoptosis does not, apoptosis, but not necrosis of host cells,
is regarded as an effective way to prevent the spread and
growth of MTB, and is considered to be a protective response
of the body to MTB infection.16e19
Studies have shown that a high dose of MTB exposure can
cause M/M apoptosis, whereas a low dose of MTB exposure
could not cause M/M apoptosis. However, the mechanism
for this phenomenon is not clear.20,21 The latest research
showed that the activation of P2X7 was coupled with the
apoptosis of a number of immune cells, including human
thymus cells, monocyte-derived macrophages,16,22 and
mouse microglial cells.23 The study by Lammas et al24
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was activated by ATP and was accompanied by MTB elimi-
nation. Similarly, another study proved that ATP stimula-
tion reduces the viability of MTB in MTB-infected
macrophages.25 In macrophages infected with a high dose
of MTB, increase in both P2X7 expression and ATP release
was observed, suggesting the presence of a P2X7-mediated
pathway. Furthermore, stimulation of ATP in MTB-infected
cells results in reduction of P2X7-dependent MTB replica-
tion, and this effect is closely coupled with ATP-induced
apoptosis.26 These studies strongly suggest the significant
role of P2X7 receptor in TB pathology. However, some
studies also showed that there was no difference in bacil-
lary burdens of MTB in P2X7/ versus wild-type animals,
suggesting that the P2X7 receptor is not required in the
control of pulmonary MTB infection.27 Therefore, further
study is still needed to clarify the anti-TB role of P2X7.The role of VGCC in TB pathology, cellular
immunity, and TB therapy
Apart from P2X7, another transmembrane ion channel, the
VGCC, has shown great potential as a target for anti-TB
therapy.3,4,28 VGCC is composed of one molecule each of
the a, b, a2d, and g subunits. Calcium entering the cell
through the channel is involved in a number of important
physiological functions, including muscle contraction, syn-
aptic signaling, neuroendocrine regulation, cell growth,
apoptosis, and gene expression.29,30 VGCC can affect the
expression of anti-infection genes downstream of calcium-
signaling pathway, and in turn, can affect the immunity
of immune cells and their phagocytic ability to MTB.3
VGCC is becoming a hot spot in investigating the in vitro
and in vivo regulation of protective immunity to MTB.
Several studies have demonstrated that VGCC is a promising
target for anti-TB therapy. VGCC blockers have become a
potential new candidate for TB chemotherapy.3,4,28 It has
been found that calcium influx can be increased by blocking
the L-type or R-type VGCC with specific antibodies or
inhibiting the VGCC expression using small interfering RNA
in dendritic cells (DCs). This increase in calcium influx is IP3
dependent and closely related to CICR, resulting in
enhanced proinflammatory gene expression.3 In addition,
blocking VGCC in DCs can activate T lymphocytes and
strengthen the ability of macrophages to kill MTB. Similarly,
in the infected macrophages and monocytes, blocking of
VGCC increases the expression of proinflammatory genes
and enhances the MTB inhibitory effect.3 More interest-
ingly, the peripheral blood mononuclear cells from TB pa-
tients exhibit a higher VGCC expression level than those
from healthy controls, and this expression level is signifi-
cantly reduced after chemotherapy.3 This suggests that
VGCC could become a potential indicator for TB progression
and prognosis. Finally, in vivo experiments on MTB-infected
mice showed that MTB load was decreased following the
blockage of VGCC with a specific antibody, whereas the
intracellular calcium level was increased.3,4 These obser-
vations indicate that poor calcium influx and calcium
signaling in DCs in response to mycobacterial stimulation
could be a result of increased expression of L-type and R-
type VGCC. Blocking of VGCC during MTB infection inhibitedthe VGCC function and reversed the effect of excessive
VGCC expression, and subsequently triggered the calcium
influx from the intracellular calcium store and the down-
stream calcium signaling.3 Therefore, L-type and R-type
VGCC may regulate the cellular protective immunity to MTB
by manipulating the intracellular calcium.
Recent research has applied this theory in TB experi-
mental chemotherapy. First, animal experiments in mice
showed that TB conventional chemotherapy (isoniazid
þ rifampin þ pyrazinamide, HRZ) plus L-type calcium-
channel blocker verapamil (Isoniazid þ rifampin þ pyr-
azinamideþ verapamil, HRZV) accelerated the clearance of
MTB inmice. TheHRZV regimen group exhibited quantitative
colony-forming unit (CFU) counts that were significantly
lower than theHRZ group from the 2ndweeks to the 24thweek
of treatment in C3HeB/FeJ mice. The difference in CFU
counts between theHRZVgroupand theHRZgroup continued
towiden over the course of treatment in C3HeB/FeJmice. By
contrast, the difference in CFU counts between the HRZV
group and the HRZ group in C3H/HeJmice was not significant
until the 12th week of treatment.4 These observations indi-
cate that the HRZV regimen accelerated the clearance of
MTB in both C3HeB/FeJ and C3H/HeJ mice, although
verapamil was less effective in C3H/HeJmice. Second, HRZV
combination significantly reduced the TB relapse rate and
the course of treatment compared with conventional
chemotherapy (HRZ).4,28 In both C3HeB/FeJ mice and C3H/
HeJ mice, the HRZV regimen exhibited much lower 3-month
drug-free relapse rate than theHRZ regimenafter 16, 20, and
24 weeks of treatment, indicating that much less time is
needed to ensure relapse-free treatment using the HRZV
method. Third, it was also reported that verapamil restored
the susceptibility to rifampicin in mice infected with MDR-
MTB.31 Tuberculous mice infected with MDR-MTB were
treated with verapamil plus rifampicin, and the results
showed that the combination of rifampicin and verapamil
significantly decreased the pulmonary bacillary loads (CFU)
at every time point, particularly after 60 days of treatment,
compared with the animals treated with rifampicin alone,
verapamil alone, or control animals treated with a saline
solution. This observation suggests that the presence of
verapamil in the combination is necessary for restoring the
susceptibility of MDR-MTB to rifampicin. Verapamil possibly
works by inhibiting the resistanceofMTB to thefirst-line anti-
TB drugs, thereby enhancing the effect of anti-TB drugs and
accelerating the clearance of MTB.28,32,33 At the cellular
level, the effects of verapamil may be explained in two as-
pects. First, at the MTB level, verapamil directly inhibits the
efflux pump on the MTB cell surface, thereby increasing the
concentration and acting time of anti-TB drugs in MTB
cells.4,28 Second, at the host immune cell level, blockage of
L-type calcium channel by verapamil had an impact on
intracellular calcium signaling, which strengthened the im-
munity of immune cells.31 The inhibition effects of verapamil
on drug resistance are important at both levels.
One important observation is that the MTB resistance to
anti-TB drugs persists in the caseous necrosis tissues. This is
because drug resistance persists after the death of macro-
phages, and the resistance spreads out of the macrophages
along with the drug-resistant MTB. The drug resistance is
transferred to other healthy immune cells by MTB infection,
which leads to continued drug resistance.4 The application of
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enhancing the efficacy of the existing first-line anti-TBdrugs.
In addition, the use of verapamil restores MTB susceptibility
to rifampin, and the combined chemotherapy (HRZV)
significantly reduces lung bacilli loads in BALB/c mice
infected with an MDR strain.4,28,30 These animal experiment
data suggest that the combination of verapamil with con-
ventional anti-TB drugs enhances the efficacy of chemo-
therapy and increases the susceptibility of MTB to
chemotherapy. It also shortens the course of treatment,
lowers the drug-resistance rates, and reduces the side ef-
fects. The aforementioned findings not only provide a strong
basis for future human research using a calcium-channel
blocker in the combined chemotherapy regimen, but also
provide strong evidence for calcium-channel blockers as a
type of new drug for TB therapy. Calcium-channel blockers,
such as verapamil, have been used for many years clinically
with obvious safety and advantage. We believe its partici-
pation in TB therapy will benefit TB patients.
Future directions in anti-TB research related
to VGCC
MDR-TB in immune-compromised population is a major
challenge in TB prevention and treatment. The combina-
tion of the first-line anti-TB drugs with verapamil has pro-
vided a potential solution for this challenge. Verapamil
regulates VGCC to trigger the intracellular calcium signaling
and enhance the cellular immunity to MTB. VGCC expres-
sion may also be a marker for TB progress and therapeutic
effect. VGCC modulation is therefore a crucial factor in
studying the mechanism of TB infection and developing new
therapeutic methods. The following aspects should be
explored further to understand the roles of VGCC in TB
pathology and future drug development.
Targeting VGCC to enhance cellular immunity and
reduce MTB load
As an intracellular second messenger, calcium regulates
important physiological functions and gene expression.
Factors affecting calcium-signaling pathway may affect
calcium regulation. We have reviewed that calcium-
channel blockers inhibit the membrane VGCC, subse-
quently activating the expression of a series of cytokines
(especially IL-12) and transcription factors, and triggering
the calcium release from ER through the IP3R and RyR cal-
cium channels. These effects upregulate a series of down-
stream gene expression, especially genes related to anti-
infection, and enhance the immunity of immune cells to
MTB and reduce MTB load, and ultimately strengthen the
immune system. However, how and to what extent calcium
achieves these effects and how the calcium signaling is
regulated in MTB infection still need further investigation.
Explore the potential of VGCC blocker to enhance
the anti-MTB chemotherapeutic effect
The current TB chemotherapy regimen is challenged by drug
resistance, and therefore the development of new drugs ornew treatmentmethod has become imperative. Combination
of the conventional TB chemotherapy regimen with VGCC
blockers may provide a newmethod of chemotherapy to help
solve the problem of drug resistance, enhance the thera-
peutic effect of conventional chemotherapy, shorten the
course of treatment, and improve the tolerance of patients.
However, VGCC blockers may produce cardiovascular side
effects (e.g., tachycardia, low blood pressure, and
arrhythmia), nervous system sideeffects (e.g., headache and
dizziness), and gastrointestinal side effects (e.g., con-
stipation and vomiting). Therefore, further study is still
required to provide more details on VGCC blocker efficacy
when it is used together with traditional chemotherapy drugs
in TB therapy. More studies in animals are also needed to
confirm its effects before it moves to human experiments.
Explore the relationship between the changes in
the immune cell VGCC expression and the progress
and prognosis of TB
It was found in recent years that the expression level of ion
channel is upregulated in many diseases, especially those
related to the immune system, such as cancer. In cancer,
the upregulation is closely related to cancer cell prolifer-
ation, invasion, and metastasis and could be a sign of ma-
lignancy. Similarly, VGCC upregulation is observed in MTB-
infected immune cells, which could be a cellular anti-
infection response related to stress stimulation and reflects
a self-protection mechanism. Therefore, it would be
interesting to investigate the relationship between VGCC
expression and TB infection and to explore the possibility of
using VGCC expression level as a biomarker for TB progress,
severity, and prognosis.
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